The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on December 23, Frontera Therapeutics submitted a listing application to the main board of the Hong Kong Stock Exchange, with UBS Securities HongKong Limited and Haitong International Capital Co., Ltd. as co-sponsors. According to the prospectus, Frontera Therapeutics is a clinical-stage gene therapy company that focuses on the research and development of innovative therapeutics, has an international business layout, and is committed to providing safe, effective, and affordable gene therapy solutions to patients around the world. Since its establishment in 2019, the company has been committed to independently developing innovative recombinant adeno-associated virus (“rAAV”) gene therapy. The company has developed a differentiated and clinically advanced pipeline with the best global potential, particularly for ophthalmology and cardiovascular diseases.

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on December 23, Frontera Therapeutics submitted a listing application to the main board of the Hong Kong Stock Exchange, with UBS Securities HongKong Limited and Haitong International Capital Co., Ltd. as co-sponsors. According to the prospectus, Frontera Therapeutics is a clinical-stage gene therapy company that focuses on the research and development of innovative therapeutics, has an international business layout, and is committed to providing safe, effective, and affordable gene therapy solutions to patients around the world. Since its establishment in 2019, the company has been committed to independently developing innovative recombinant adeno-associated virus (“rAAV”) gene therapy. The company has developed a differentiated and clinically advanced pipeline with the best global potential, particularly for ophthalmology and cardiovascular diseases.